{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:09:08Z","timestamp":1790122148994,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["GR-2011-0234982"],"award-info":[{"award-number":["GR-2011-0234982"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00702-018-1893-1","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T04:18:37Z","timestamp":1528949917000},"page":"1373-1379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy"],"prefix":"10.1007","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-6278","authenticated-orcid":false,"given":"Tommaso","family":"Schirinzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Sancesario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Scalise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Luigi","family":"Colona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Imbriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"1893_CR1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/brain\/awv024","volume":"138","author":"A Baker-Nigh","year":"2015","unstructured":"Baker-Nigh A, Vahedi S, Goetz Davis E et al (2015) Neuronal amyloid-b accumulation within cholinergic basal forebrain in ageing and Alzheimer\u2019s disease. Brain 138:1722\u20131737. \n                    https:\/\/doi.org\/10.1093\/brain\/awv024","journal-title":"Brain"},{"key":"1893_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3233\/JAD-132195","volume":"40","author":"M Balasa","year":"2014","unstructured":"Balasa M, S\u00e1nchez-Valle R, Antonell A et al (2014) Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. J Alzheimers Dis 40:919\u2013927. \n                    https:\/\/doi.org\/10.3233\/JAD-132195","journal-title":"J Alzheimers Dis"},{"key":"1893_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Publ Gr 6:131\u2013144. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2010.4","journal-title":"Nat Publ Gr"},{"key":"1893_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mds.26656","volume":"31","author":"K Blennow","year":"2016","unstructured":"Blennow K, Biscetti L, Eusebi P, Parnetti L (2016) Cerebrospinal fluid biomarkers in Alzheimer\u2019s and Parkinson\u2019s diseases\u2014from pathophysiology to clinical practice. Mov Disord 31:836\u2013847. \n                    https:\/\/doi.org\/10.1002\/mds.26656","journal-title":"Mov Disord"},{"key":"1893_CR5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1212\/WNL.0b013e3181dc1a55","volume":"74","author":"S Gilman","year":"2010","unstructured":"Gilman S, Koeppe RA, Nan B et al (2010) Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74:1416\u20131423. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1a55","journal-title":"Neurology"},{"key":"1893_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864. \n                    https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"1893_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1893_CR8","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","volume":"22","author":"DJ Irwin","year":"2016","unstructured":"Irwin DJ (2016) Tauopathies as clinicopathological entities. Parkinsonism Relat Disord 22:S29\u2013S33. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.020","journal-title":"Parkinsonism Relat Disord"},{"key":"1893_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jnnp-2017-315857","volume":"88","author":"E Jabbari","year":"2017","unstructured":"Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry 88:883\u2013888. \n                    https:\/\/doi.org\/10.1136\/jnnp-2017-315857","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1893_CR10","doi-asserted-by":"publisher","first-page":"42751","DOI":"10.1074\/jbc.M112.380642","volume":"287","author":"CM Karch","year":"2012","unstructured":"Karch CM, Jeng AT, Goate AM (2012) Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem 287:42751\u201342762. \n                    https:\/\/doi.org\/10.1074\/jbc.M112.380642","journal-title":"J Biol Chem"},{"key":"1893_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1017\/S0317167100009392","volume":"35","author":"J Keith-Rokosh","year":"2008","unstructured":"Keith-Rokosh J, Ang LC (2008) Progressive supranuclear palsy: a review of co-existing neurodegeneration. Can J Neurol Sci 35:602\u2013608","journal-title":"Can J Neurol Sci"},{"key":"1893_CR12","doi-asserted-by":"publisher","first-page":"1326-e77","DOI":"10.1111\/ene.13389","volume":"24","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Andreasson U, Liman V et al (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol 24:1326-e77. \n                    https:\/\/doi.org\/10.1111\/ene.13389","journal-title":"Eur J Neurol"},{"key":"1893_CR13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/mds.26105","volume":"29","author":"AE Lang","year":"2014","unstructured":"Lang AE (2014) Clinical heterogeneity in progressive supranuclear palsy: challenges to diagnosis, pathogenesis and future therapies. Mov Disord 29:1707\u20131709. \n                    https:\/\/doi.org\/10.1002\/mds.26105","journal-title":"Mov Disord"},{"key":"1893_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1\u20139","journal-title":"Neurology"},{"key":"1893_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/jnnp-2013-307539","volume":"85","author":"N Magdalinou","year":"2014","unstructured":"Magdalinou N, Lees AJ, Zetterberg H (2014) Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 85:1065\u20131075. \n                    https:\/\/doi.org\/10.1136\/jnnp-2013-307539","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1893_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86:1240\u20131247. \n                    https:\/\/doi.org\/10.1136\/jnnp-2014-309562","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1893_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2014.00252","volume":"6","author":"A Martorana","year":"2014","unstructured":"Martorana A, Koch G (2014) Is dopamine involved in Alzheimer\u2019s disease? Front Aging Neurosci 6:1\u20136. \n                    https:\/\/doi.org\/10.3389\/fnagi.2014.00252","journal-title":"Front Aging Neurosci"},{"key":"1893_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/cns.12476","volume":"21","author":"A Martorana","year":"2015","unstructured":"Martorana A, Di Lorenzo F, Belli L et al (2015) Cerebrospinal fluid A\u03b242 Levels: when physiological become pathological state. CNS Neurosci Ther 21:921\u2013925. \n                    https:\/\/doi.org\/10.1111\/cns.12476","journal-title":"CNS Neurosci Ther"},{"key":"1893_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004609","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer B, Caspell-Garcia CJ, Coffey CS et al (2017) Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000004609","journal-title":"Neurology"},{"key":"1893_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jns.2005.05.015","volume":"237","author":"M Noguchi","year":"2005","unstructured":"Noguchi M, Yoshita M, Matsumoto Y et al (2005) Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 237:61\u201365. \n                    https:\/\/doi.org\/10.1016\/j.jns.2005.05.015","journal-title":"J Neurol Sci"},{"key":"1893_CR21","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/mds.26054","volume":"29","author":"G Respondek","year":"2014","unstructured":"Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758\u20131766. \n                    https:\/\/doi.org\/10.1002\/mds.26054","journal-title":"Mov Disord"},{"key":"1893_CR22","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV et al (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90:e273\u2013e281. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000004859","journal-title":"Neurology"},{"key":"1893_CR23","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3233\/JAD-160975","volume":"55","author":"GM Sancesario","year":"2017","unstructured":"Sancesario GM, Toniolo S, Chiasserini D et al (2017) The clinical use of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: the Italian selfie. J Alzheimers Dis 55:1659\u20131666. \n                    https:\/\/doi.org\/10.3233\/JAD-160975","journal-title":"J Alzheimers Dis"},{"key":"1893_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fneur.2015.00086","volume":"6","author":"T Schirinzi","year":"2015","unstructured":"Schirinzi T, Sancesario GM, Ialongo C et al (2015) A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. Front Neurol 6:86. \n                    https:\/\/doi.org\/10.3389\/fneur.2015.00086","journal-title":"Front Neurol"},{"key":"1893_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/mds.26620","volume":"31","author":"T Schirinzi","year":"2016","unstructured":"Schirinzi T, Madeo G, Martella G et al (2016) Early synaptic dysfunction in Parkinson\u2019s disease: insights from animal models. Mov Disord 31:802\u2013813. \n                    https:\/\/doi.org\/10.1002\/mds.26620","journal-title":"Mov Disord"},{"key":"1893_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1743-6","author":"T Schirinzi","year":"2017","unstructured":"Schirinzi T, Di Lazzaro G, Colona VL et al (2017a) Assessment of serum uric acid as risk factor for tauopathies. J Neural Transm. \n                    https:\/\/doi.org\/10.1007\/s00702-017-1743-6","journal-title":"J Neural Transm"},{"key":"1893_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1786-8","author":"T Schirinzi","year":"2017","unstructured":"Schirinzi T, Di Lazzaro G, Sancesario GM et al (2017b) Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer\u2019s disease. J Neural Transm. \n                    https:\/\/doi.org\/10.1007\/s00702-017-1786-8","journal-title":"J Neural Transm"},{"key":"1893_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1842-z","author":"T Schirinzi","year":"2018","unstructured":"Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018) Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. J Neural Transm. \n                    https:\/\/doi.org\/10.1007\/s00702-018-1842-z","journal-title":"J Neural Transm"},{"key":"1893_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","volume":"221","author":"R Schliebs","year":"2011","unstructured":"Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:555\u2013563. \n                    https:\/\/doi.org\/10.1016\/j.bbr.2010.11.058","journal-title":"Behav Brain Res"},{"key":"1893_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/mds.22895","volume":"25","author":"SD S\u00fcssmuth","year":"2010","unstructured":"S\u00fcssmuth SD, Uttner I, Landwehrmeyer B et al (2010) Differential pattern of brain-specific CSF proteins tau and amyloid-\u03b2 in Parkinsonian syndromes. Mov Disord 25:1284\u20131288. \n                    https:\/\/doi.org\/10.1002\/mds.22895","journal-title":"Mov Disord"},{"key":"1893_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-018-0359-x","volume":"10","author":"CE Teunissen","year":"2018","unstructured":"Teunissen CE, Otto M, Engelborghs S et al (2018) White paper by the society for CSF analysis and clinical neurochemistry: overcoming barriers in biomarker development and clinical translation. Alzheimers Res Ther 10:30. \n                    https:\/\/doi.org\/10.1186\/s13195-018-0359-x","journal-title":"Alzheimers Res Ther"},{"key":"1893_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele H, Bibl M, Engelborghs S et al (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative. Alzheimers Dement 8:65\u201373. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2011.07.004","journal-title":"Alzheimers Dement"},{"key":"1893_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp-2014-308004","volume":"86","author":"D Wagshal","year":"2015","unstructured":"Wagshal D, Sankaranarayanan S, Guss V et al (2015) Divergent CSF \u03c4 alterations in two common tauopathies: Alzheimer\u2019s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 86:244\u2013250. \n                    https:\/\/doi.org\/10.1136\/jnnp-2014-308004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1893_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2017.12.016","volume":"48","author":"JL Whitwell","year":"2018","unstructured":"Whitwell JL, Ahlskog JE, Tosakulwong N et al (2018) Pittsburgh compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer\u2019s disease in progressive supranuclear palsy. Parkinsonism Relat Disord 48:3\u20139. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2017.12.016","journal-title":"Parkinsonism Relat Disord"},{"key":"1893_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","volume":"8","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270\u2013279. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(09)70042-0","journal-title":"Lancet Neurol"},{"key":"1893_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"J-T Yu","year":"2017","unstructured":"Yu J-T, Lang AE, Boxer AL et al (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552\u2013563. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(17)30157-6","journal-title":"Lancet Neurol"},{"key":"1893_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","volume":"126","author":"J Zhang","year":"2013","unstructured":"Zhang J, Mattison HA, Liu C et al (2013) Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 126:671\u2013682. \n                    https:\/\/doi.org\/10.1007\/s00401-013-1121-x","journal-title":"Acta Neuropathol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1893-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1893-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1893-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T19:20:22Z","timestamp":1560453622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1893-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1893-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"2 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were conducted in agreement with indications of \u201cgood clinical practice\u201d, and either to institutional\/local ethical standards or ethical principles of Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from each participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}